Opinion

The biologics development and approval process for pharmaceutical companies around the world is typically long and complex, which increases the risk of inaccurately forecasting demand

Dispense As Written

Sharing clinical data—EvGen—will improve both drug development and health outcomes analysis

A new, market-driven model of drug development and commercialization is appearing*

Looking at 'cost' and 'value' under different evaluation processes

Looking at the essential value of well-managed supply chains

HDMA seeks to encourage more outreach to business partners and government

Despite a flurry of specialty pharmaceuticals in innovative formats, traditional powder-based dosages will always be a mainstay

A Common Universal Patient de-IDentifier could greatly enhance the value of industry data assets

Fees paid to FDA by small generic manufacturers are financially 'unfair'

The pharma industry needs to go farther in adapting to new marketplace realities

The second edition of an essential business planner's library

"If we had asked them, they would have asked for faster horses." ~ Henry Ford

While the pharma industry is growing more dependent on companion diagnostics, test developers face an uncertain business model

Logistics managers in life sciences and personal care focus on transportation capacity

Medical marijuana and biosimilars are two topics where 'the will of the people' push decisions